Autopsy report · NCT04549363
Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin
Cause of deathOther
“The study has been terminated for reasons pertaining to feasibility”
Life of this trial
- Registered 3 months before it started.
- Ran for about 1 year 11 months before it stopped.
- 16 participants enrolled.
- Results were posted on the registry 1 year 1 month after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- GlaxoSmithKline
- Sponsor type
- Industry
- Conditions
- Multiple Myeloma
- Interventions
- Belantamab mafodotin
- Participants
- 16
- Sites
- 6
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.